Publications by authors named "Frederic Reu"

Claim this Profile
A
Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study.
Yumeng Zhang, Lauren Duncanson, Jason Brayer, Frederic Reu, Doris Hansen

Clin Lymphoma Myeloma Leuk· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic Targeting of Protein Disulfide Isomerase PDIA1 in Multiple Myeloma.
Metis Hasipek, Dale Grabowski, Yihong Guan, Raghunandan Reddy Alugubelli, Anand D Tiwari, Frederic J Reu

Cancers (Basel)· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.
Jack Khouri, Beth M Faiman, Dale Grabowski, Reda Z Mahfouz, Shahper N Khan, Frederic J Reu

Semin Hematol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).
Brian G M Durie, Antje Hoering, Rachael Sexton, Muneer H Abidi, Joshua Epstein, Frederic J Reu

Blood Cancer J· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-Dose Lenalidomide After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation With Bortezomib as Graft-Versus-Host Disease Prophylaxis in High-Risk Multiple Myeloma.
Jack Khouri, Frederic Reu, Navneet S Majhail, Aaron Gerds, Deepa Jagadeesh

Clin Lymphoma Myeloma Leuk· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab proves safe and highly effective in AL amyloidosis.
Jack Khouri, Andrew Kin, Bicky Thapa, Frederic J Reu, Naresh Bumma

Br J Haematol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma.
Yi Hu, Jianhong Lin, Hua Fang, Jing Fang, Chen Li, Frederic Reu

Leukemia· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis.
Surbhi Sidana, Mayur Narkhede, Paul Elson, Debbie Hastings, Beth Faiman, Frederic J Reu

PLoS One· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Brian G M Durie, Antje Hoering, Muneer H Abidi, S Vincent Rajkumar, Joshua Epstein, Frederic Reu

Lancet· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
Shaji K Kumar, Natalie S Callander, Melissa Alsina, Djordje Atanackovic, J Sybil Biermann, Frederic J Reu

J Natl Compr Canc Netw· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma.
Rachid C Baz, Jeffrey A Zonder, Cristina Gasparetto, Frederic J Reu, Vincent Strout

Oncol Ther· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response.
Yuhuan Zheng, Qiang Wang, Tianshu Li, Jianfei Qian, Yong Lu, Frederic Reu

J Natl Cancer Inst· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microarray-based analysis and clinical validation identify ubiquitin-conjugating enzyme E2E1 (UBE2E1) as a prognostic factor in acute myeloid leukemia.
Hongmei Luo, Yu Qin, Frederic Reu, Sujuan Ye, Yang Dai

J Hematol Oncol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma.
Sergei Vatolin, James G Phillips, Babal K Jha, Shravya Govindgari, Jennifer Hu, Frederic J Reu

Cancer Res· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.
Kenneth C Anderson, Melissa Alsina, Djordje Atanackovic, J Sybil Biermann, Jason C Chandler, Frederic J Reu

J Natl Compr Canc Netw· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural optimization of non-nucleoside DNA methyltransferase inhibitor as anti-cancer agent.
Bo Zhong, Sergei Vatolin, Nethrie D Idippily, Rati Lama, Laila A Alhadad, Frederic J Reu

Bioorg Med Chem Lett· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemokines CCL2, 3, 14 stimulate macrophage bone marrow homing, proliferation, and polarization in multiple myeloma.
Yi Li, Yuhuan Zheng, Tianshu Li, Qiang Wang, Jianfei Qian, Frederic Reu

Oncotarget· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2.
Andrew R Lavik, Fei Zhong, Ming-Jin Chang, Edward Greenberg, Yuvraj Choudhary, Frederic J Reu

Oncotarget· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.
Yogen Saunthararajah, Mikkael Sekeres, Anjali Advani, Reda Mahfouz, Lisa Durkin, Frederic Reu

J Clin Invest· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.
Aleksandr Lazaryan, Mohamad A Hussein, Frederic J Reu, Beth Faiman, Becky Habecker

Am J Hematol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Direct chromatin PCR (DC-PCR): hypotonic conditions allow differentiation of chromatin states during thermal cycling.
Sergei Vatolin, Shahper N Khan, Frederic J Reu

PLoS One· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis.
Christoph J Heuck, Jayesh Mehta, Tushar Bhagat, Krishna Gundabolu, Yiting Yu, Frederic Reu

J Immunol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.
David S Siegel, Thomas Martin, Michael Wang, Ravi Vij, Andrzej J Jakubowiak, Frederic J Reu

Blood· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.
Ravi Vij, Michael Wang, Jonathan L Kaufman, Sagar Lonial, Andrzej J Jakubowiak, Frederic J Reu

Blood· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies.
Yogen Saunthararajah, Pierre Triozzi, Brian Rini, Arun Singh, Tomas Radivoyevitch, Frederic Reu

Semin Oncol· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis